Your browser doesn't support javascript.
loading
Artificial Intelligence-Based Segmentation of Residual Tumor in Histopathology of Pancreatic Cancer after Neoadjuvant Treatment.
Janssen, Boris V; Theijse, Rutger; van Roessel, Stijn; de Ruiter, Rik; Berkel, Antonie; Huiskens, Joost; Busch, Olivier R; Wilmink, Johanna W; Kazemier, Geert; Valkema, Pieter; Farina, Arantza; Verheij, Joanne; de Boer, Onno J; Besselink, Marc G.
  • Janssen BV; Department of Surgery, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Theijse R; Department of Pathology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • van Roessel S; Department of Surgery, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • de Ruiter R; Department of Pathology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Berkel A; Department of Surgery, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Huiskens J; SAS Institute Besloten Vennootschap, 1272 PC Huizen, The Netherlands.
  • Busch OR; SAS Institute Besloten Vennootschap, 1272 PC Huizen, The Netherlands.
  • Wilmink JW; SAS Institute Besloten Vennootschap, 1272 PC Huizen, The Netherlands.
  • Kazemier G; Department of Surgery, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Valkema P; Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Farina A; Department of Surgery, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
  • Verheij J; Department of Pathology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • de Boer OJ; Department of Pathology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Besselink MG; Department of Pathology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
Cancers (Basel) ; 13(20)2021 Oct 12.
Article en En | MEDLINE | ID: mdl-34680241
ABSTRACT

BACKGROUND:

Histologic examination of resected pancreatic cancer after neoadjuvant therapy (NAT) is used to assess the effect of NAT and may guide the choice for adjuvant treatment. However, evaluating residual tumor burden in pancreatic cancer is challenging given tumor response heterogeneity and challenging histomorphology. Artificial intelligence techniques may offer a more reproducible approach.

METHODS:

From 64 patients, one H&E-stained slide of resected pancreatic cancer after NAT was digitized. Three separate classes were manually outlined in each slide (i.e., tumor, normal ducts, and remaining epithelium). Corresponding segmentation masks and patches were generated and distributed over training, validation, and test sets. Modified U-nets with varying encoders were trained, and F1 scores were obtained to express segmentation accuracy.

RESULTS:

The highest mean segmentation accuracy was obtained using modified U-nets with a DenseNet161 encoder. Tumor tissue was segmented with a high mean F1 score of 0.86, while the overall multiclass average F1 score was 0.82.

CONCLUSIONS:

This study shows that artificial intelligence-based assessment of residual tumor burden is feasible given the promising obtained F1 scores for tumor segmentation. This model could be developed into a tool for the objective evaluation of the response to NAT and may potentially guide the choice for adjuvant treatment.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Article